| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.21 | 4e-06 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0003 |
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0004 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0005 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | -0.12 | 0.003 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.085 | 0.004 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.005 |
| mRNA | BMS-345541 | CTRPv2 | pan-cancer | AAC | -0.098 | 0.006 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.081 | 0.006 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.1 | 0.006 |